More Stories

Informist, Friday, Jun. 5, 2026

MUMBAI – Shares of pharmaceutical companies will likely be in a range in the coming week with no sector-specific triggers. Technical analysts expect the traders to buy pharmaceutical stocks on every dip. While there is some comfort in valuations, a sharp rise in these stocks is unlikely, some analysts said. From a month's perspective, some research heads had said that these stocks would be resilient. However, the upcoming monsoon season is watched out for by companies heavy on acute drugs, analysts said.

While these companies are not directly affected by the impact of West Asia war, and far insulated from the energy shocks, some analysts worry that shortage of ammonia may hit supply of sourcing of certain active pharmaceutical ingredients and solvents. From a short-term perspective, this is the main worry, an analyst said.

Further, if the supply of packaging materials comes under constraint, that would be a major worry for the entire sector. The rise in prices of these materials is not a major concern, analysts said. In the March quarter, the rise in costs due to these was already visible. The overall expenses of pharmaceutical and healthcare companies belonging to Nifty 500 index rose 14% to a 10-quarter high.

The upcoming monsoon season will be key for acute drug makers such as Mankind Pharma Ltd. and Alkem Laboratories as infectious diseases, especially dengue and malaria, increase during this period. In the June quarter last year, the season was weak, and, hence, a low base is also seen in favour of these companies. The acute drug market is seen growing 7-8% this year, an analyst said. 

On Friday, the Nifty Pharma index closed at 24248.05 points, up 0.3%. During this week, the sectoral index declined just 0.4% as compared to a 0.8% fall in Nifty 50. This week, Wockhardt and Glenmark Pharmaceuticals fell the most whereas Ipca Laboratories and Laurus Labs outperformed with 6-8% gains. In the near-term, a dip towards 23800-23500 points would attract buying opportunities, Vipin Kumaar, assistant vice-president, technical and derivatives, at Globe Capital Market, said. On the other hand, gains will be capped at 24800 points on an immediate basis, he added.

TOP HEADLINES

* Glenmark Pharma arm launches lacosamide injection in US
* Lupin gets US FDA approval for Ranluspec injection
* Aurobindo Pharma gets US FDA final approval for tofacitinib tablets
* Wockhardt to launch Zaynich in US, Europe, emerging markets in next 2 years
* Cipla opens sputum inflammometry laboratory at Mumbai lung wellness centre
* Aurobindo Pharma inaugrates biologics mfg facility in Telangana
* US FDA classifies Granules India US unit as 'voluntary action indicated'
* State Pollution Control Board revokes closure of Piramal Pharma Gujarat unit
* US FDA warns Zydus Life as sub-standard purified talc used at Baddi unit
* Lupin, Natco Pharma get US FDA approval for Eribulin Mesylate injection
* Alkem Lab promoters sell entire 1% stake for INR 6.44 bln in block deal
* West Asia crisis to slow MSME revenue growth by 100 bps in FY27, says Crisil
* US FDA approves Concord Biotech's ANDA for mycophenolate mofetil drug
* Alkem Lab launches semaglutide pre-filled syringes starting INR 350
* HC asks drug regulatory body to decide on plea vs nod to Zydus' semaglutide
* HC allows Intas Pharma to sell cancer drug in Sun Pharma arm trademark case
* Analyst Concall:Glenmark Pharma targets INR 170 bln-INR 180 bln revenue FY27
* Wockhardt gets US FDA approval for antibiotic Zaynich
* Jubilant Pharmova arm's JV gets US FDA warning letter for Canada mfg unit
* Earnings Review: Glenmark Pharma PAT jumps manifold Q4 despite one-time cost
* Lupin gets US FDA approval for bioequivalent of Sutab tablets
* Lupin says to complete acquisition of stake in Philippines arm in July
 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

End

Reported by Gopika Balasubramanium

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.